#long-acting injectables

Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.

Periodic infusions of such antibodies may eventually become a new way of treating the virus.

ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.

This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.

Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.

One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.

HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.

A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.

A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.

This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

A trial of long-acting cabotegravir given every eight weeks found that it yielded adequate drug levels and was well tolerated.

Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.